Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats

E. J. van Hoogdalem, C. D. Heijligers-Feijen, R. A. Mathôt, A. T. Wackwitz, J. B. van Bree, J. C. Verhoef, A. G. de Boer, D. D. Breimer

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)

Abstract

The effects of sodium tauro-24,25-dihydrofusidate (STDHF), an enhancer of nasal insulin absorption, on the rectal absorption of cefoxitin and desglycinamide arginine vasopressin (DGAVP) were evaluated in the rat. Cefoxitin and DGAVP proved to be poorly absorbed rectally without STDHF, but their bioavailability was considerably increased by STDHF in concentrations of 0.15 to 8% w/v. Both rectal infusion and rectal bolus delivery resulted in complete cefoxitin absorption at 4% w/v of STDHF. Delivery rate appeared to be an important factor in the effect of 4% w/v of STDHF on DGAVP bioavailability; on infusion a mean DGAVP bioavailability (+/- S.D.) of 47 +/- 12% was obtained, whereas after bolus delivery it amounted to 27 +/- 6%. For both compounds the effect of STDHF was significant at 0.5% w/v. It is concluded that STDHF is capable of actively enhancing the rectal absorption of poorly absorbed drugs, including small peptides
Original languageEnglish
Pages (from-to)741-744
JournalJournal of Pharmacology and Experimental Therapeutics
Volume251
Issue number2
Publication statusPublished - 1989

Cite this